# A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

> **NCT05396300** · PHASE1 · RECRUITING · sponsor: **Weijia Fang, MD** · enrollment: 110 (estimated)

## Conditions studied

- Colorectal Cancer
- Solid Cancers
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** Intraperitoneal infusion of FAST CEA-targeted CAR-T
- **BIOLOGICAL:** CEA CAR-T cells
- **BIOLOGICAL:** CEA CAR-T cells

## Key facts

- **NCT ID:** NCT05396300
- **Lead sponsor:** Weijia Fang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-25
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05396300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05396300, "A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05396300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*